Navigation Links
Clinical Comparisons Between ADHD Drugs Are Less

Research has shown that there are few clinical comparisons available between the drugs for ADHD. As a result, parents seeking the best individual drug for their children with attention deficit hyperactivity disorder // have little hard evidence to help make that choice.

There are few head-to-head clinical comparisons of many ADHD medications, despite the relatively large variety of drugs prescribed for ADHD and the prevalence of the condition among children and adults, according to a new review from the Oregon Evidence-based Practice Center at the Oregon Health and Science University.

The Oregon Evidence-based Practice Center makes available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes.

The majority of the head-to-head trials identified by the Oregon reviewers compared the widely prescribed ADHD medication Ritalin with other drugs. Most of these comparative trials were short in duration, included only a small number of patients and did not measure the long-term effects of the drugs.

As for safety, the researchers found that short-term, randomized controlled trials do not provide clear evidence that any one stimulant is any more tolerable than another or that non-stimulants are more tolerable than stimulants.

None of the trials compared how well the drugs performed in terms of improving academic performance, quality of life or social skills, the researchers found.

Stimulant medications such as Ritalin and amphetamines are most often prescribed for ADHD, but the Oregon study includes several types of ADHD medications that have never been examined before in a systematic review, including newer stimulants such as modafinil and non-stimulant drugs such as Strattera (atomoxetine), antihypertensive drugs such as guanfacine and older antipsychotic drugs such as clozapine.

Limited evidence suggests that the antihypertensive dr
'"/>




Page: 1 2

Related medicine news :

1. Clinical trials need to be more frank
2. Physicians Lack Clinical Guidelines For Treating Elderly With Multiple Illnesses
3. The Growing Rise In Clinical Research Could Lead To A Compromise In Quality Of Research And Ethics
4. A Novel System For Clinical Banking Of Umbilical Cord Blood
5. Clinical Renal Trails Do Not Have Sufficient Women Participants
6. Clinical Trials of New Drug Febuxostat Show Promise in Gout Treatment
7. Clinical Trials Of New Anti-Cancer Drug To Be Initiated In New Zealand
8. Green Tea Consumption Found To Improve Clinical Outcome In Cancer Patients
9. Cancer Clinical Research in India
10. New Generation Clinical Trials Could Save Time And Money, Improve Patient Care
11. Clinical Impact of Activity and Abdominal Pressure on Pelvic Floor Dysfunction Need to Be Further Analyzed
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Clinical Comparisons Between ADHD Drugs Are Less

(Date:7/26/2014)... (PRWEB) July 26, 2014 ... recently updated by Vkool.com, this is a ... safe methods for treating all types of ...     Tinnitus due to Ménière's ... ,     Nerve pathway tinnitus , ...
(Date:7/26/2014)... Columbus, OH (PRWEB) July 26, 2014 The ... medical guidelines list that includes a new medication guide for ... as a serious side-effect of taking the topical low testosterone ... notes that AbbVie Inc., the makers of the low testosterone ... include symptoms of pain, swelling or redness as signs of ...
(Date:7/26/2014)... Wa (PRWEB) July 26, 2014 According ... updated by Vkool.com, this is a comprehensive guide that ... unwanted tattoos . This book also teaches them ... imitate common medical procedures in their own home for ... that "Get Rid Tattoo Naturally" book includes step-by-step tutorials ...
(Date:7/25/2014)... Texas (PRWEB) July 26, 2014 ... and China Gel Permeation Chromatography Industry” is ... the Global and China Gel Permeation Chromatography ... Chromatography information, including Gel Permeation Chromatography definition, ... well as industry overview. This research covers ...
(Date:7/25/2014)... July 25, 2014 A federal judge ... in two DePuy Pinnacle hip lawsuits ( http://www.depuypinnacle-lawsuit.com/ ... the claims to go before a jury on September ... rendered on July 18th, U.S. District Judge Ed Kinkeade ... two Plaintiffs’ claims may proceed to trial against Johnson ...
Breaking Medicine News(10 mins):Health News:Tinnitus Miracle Book Review Exposes Thomas Coleman's Guide for Treating Tinnitus – Vkool.com 2Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 2Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 3Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 4Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 5Health News:"Get Rid Tattoo Naturally" Book Review Exposes Jason Carter's Tattoo Removal Guide – Vkool.com 2Health News:"Get Rid Tattoo Naturally" Book Review Exposes Jason Carter's Tattoo Removal Guide – Vkool.com 3Health News:2014 China & Global GPC Industry - Gel Permeation Chromatography Development Trends Now at DeepResearchReports.com 2Health News:2014 China & Global GPC Industry - Gel Permeation Chromatography Development Trends Now at DeepResearchReports.com 3Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 2Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 3Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 4
... -- People with heart conditions who take vitamins may be ... according to a new study. Researchers from the Intermountain ... heartbeat -- known as atrial fibrillation -- what they knew ... were also asked how well they followed their prescription for ...
... Healthy, new heart cells have been generated by animals ... derived from cardiac biopsies or "cardiospheres," according to research ... and Biomedical Sciences. , The research is being ... the American Heart Association in Orlando. , The UB ...
... which can develop into any cell type in the ... drive their metabolic activities. In contrast, mature ... mitochondria to convert sugar and oxygen into carbon dioxide ... phosphorylation for their metabolic needs. How cells ...
... surgical techniques on toy animals before having to perform operations ... the same time, the use of laboratory animals is minimised. ... - the Faculty of Life Sciences at the University of ... the ,teddy laboratory, strengthens learning and the teaching environment. ...
... -- Preliminary trials indicate that a new drug designed ... shows considerable promise, both on its own and in ... is part of a class of so-called "cholesteryl ester ... CETP medication to undergo testing as a means to ...
... Reinberg HealthDay Reporter , TUESDAY, Nov. 15 (HealthDay ... the statin drug Zocor (simvastatin) to help lower their cholesterol ... Even though niacin appeared to increase HDL cholesterol -- the ... in the blood, it did not reduce the risk of ...
Cached Medicine News:Health News:Heart Patients Using Vitamins May Take Meds Improperly 2Health News:Heart Patients Using Vitamins May Take Meds Improperly 3Health News:New heart cells increase by 30 percent after stem cell infusion 2Health News:UCLA stem cell researchers uncover mechanism that regulates human pluripotent stem cell metabolism 2Health News:UCLA stem cell researchers uncover mechanism that regulates human pluripotent stem cell metabolism 3Health News:UCLA stem cell researchers uncover mechanism that regulates human pluripotent stem cell metabolism 4Health News:Surgery on toy animals lessens anxiety of veterinary students 2Health News:Cholesterol Drug Shows Promise in Early Research 2Health News:Cholesterol Drug Shows Promise in Early Research 3Health News:No Benefit From Niacin for Heart Patients in Study 2Health News:No Benefit From Niacin for Heart Patients in Study 3
(Date:7/24/2014)... Kan. , July 24, 2014  Parnell ... two compounds that will be added to Parnell,s ... Australian-based CIMTECH Pty Ltd, a biotechnology company. The ... 122 have shown promise in bone regeneration and ... to develop the compounds for the veterinary market ...
(Date:7/24/2014)... MARSEILLE , Frankreich, July 24, ... , Weltweite Exklusivlizenz der Universität ... von Tests auf SF3B1-Mutationen, einschließlich von Next-Generation-Sequencing ... Test weist Mutationen des SF3B1-Gens nach, die ... günstigen Krankheitsverlauf vermuten lassen  QIAGEN ...
(Date:7/24/2014)... -- Abaxis, Inc. (NasdaqGS: ABAX ), a medical ... financial results for the first fiscal quarter ended June ... Revenues of $47.5 million, up 10% over last year,s ... 50% over last year,s comparable quarter. Revenues ... up 20% over last year,s comparable quarter. , ...
Breaking Medicine Technology:Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 2Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11
... Pieris AG presented the results ... most advanced Anticalin ® , PRS-050, an anti-VEGF ... Conference held in San Francisco, California.  The dose-escalation ... tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of PRS-050 ...
... /PRNewswire-Asia-FirstCall/ -- Concord Medical Services Holdings Limited ("Concord ... operator of the largest network of radiotherapy and diagnostic imaging ... for the third quarter ended September 30, 2011. ... revenues were RMB124.7 million ($19.6 million)(A) in the third quarter ...
Cached Medicine Technology:Pieris Announces Results and Successful Completion of its PRS-050 Anticalin Phase I Trial at AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference 2Pieris Announces Results and Successful Completion of its PRS-050 Anticalin Phase I Trial at AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference 3Concord Medical Reports Third Quarter 2011 Financial Results 2Concord Medical Reports Third Quarter 2011 Financial Results 3Concord Medical Reports Third Quarter 2011 Financial Results 4Concord Medical Reports Third Quarter 2011 Financial Results 5Concord Medical Reports Third Quarter 2011 Financial Results 6Concord Medical Reports Third Quarter 2011 Financial Results 7Concord Medical Reports Third Quarter 2011 Financial Results 8Concord Medical Reports Third Quarter 2011 Financial Results 9Concord Medical Reports Third Quarter 2011 Financial Results 10Concord Medical Reports Third Quarter 2011 Financial Results 11Concord Medical Reports Third Quarter 2011 Financial Results 12Concord Medical Reports Third Quarter 2011 Financial Results 13Concord Medical Reports Third Quarter 2011 Financial Results 14Concord Medical Reports Third Quarter 2011 Financial Results 15
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 19.0 mm and length 21 mm....
... The BacT/Alert 3D Select ... art, automated microbial detection system ... fluid and mycobacteria culturing. This ... data management or laboratory information ...
IDS Rapid ANA II System, a microbial identification system....
IDS Rapid One, a microbial identification system....
Medicine Products: